Arbutus Biopharma Corporation (ABUS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.55 |
| Open | 4.59 |
| Day High | 4.79 |
| Day Low | 4.47 |
| 52-Week High | 5.1 |
| 52-Week Low | 3.04 |
| Volume | 5.25M |
| Average Volume | 1.75M |
| Market Cap | 892.87M |
| PE | 5.45 |
| EPS | 0.83 |
| Moving Average 50 Days | 4.37 |
| Moving Average 200 Days | 4.42 |
| Change | -0.03 |
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
GlobeNewswire Inc.
Mar 03, 2026 9:15 PM GMT
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed pate
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
GlobeNewswire Inc.
Jun 25, 2025 11:30 AM GMT
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2